surmount-1 tirzepatide trial obesity without diabetes Effect of on Body Weight and Control in Adults With Type 1 Diabetes and Overweight or SURMOUNT-3 study design This is

[1] [3] Clinical trials, including the SURMOUNT and SURPASS programmes, have demonstrated significant weight loss that varies by dose and populationin the SURMOUNT-1 trial of non-diabetic adults, mean weight loss ranged from approximately 15% (5 mg dose) to 20% (15 mg dose) after 72 weeks

Every interaction feels personal, relaxed, and sincere

Why Are People Switching From Tirzepatide to Retatrutide Many people begin considering switching from Tirzepatide to Retatrutide after their weight loss progress stalls or when they want improved blood sugar outcomes

Secure patient portal allows direct communication and ongoing treatment tracking

48 weeks (standard cycle) 6-8 x 10 mg vials Maintenance at 9 mg weekly drives most of the total